OKYO Pharma Ltd (OKYO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
OKYO currently has 37.6M outstanding shares. with significant dilution risk as 79.1M authorized shares could dilute existing holders by 210.4%. The company has diluted shareholders by 11.15% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 18, 2025 |
20-F filing | 37.6M shares outstanding |
38M | 79M |
| Aug 13, 2024 |
20-F filing | 33.8M shares outstanding |
34M | 79M |
| Aug 15, 2023 |
20-F filing | 25.6M shares outstanding |
26M | 79M |
| Jun 08, 2023 |
F-3 filing: OKYO Pharma files an F-3 form to offer ordinary shares, warrants to purchase ordinary shares, and a combination of such securities, separately or as units, up to $100,000,000. |
290M | 79M |
| May 17, 2023 |
F-1 filing: This F-1 filing relates to the resale of 10,153,281 ordinary shares by selling shareholders. |
290M | 10M |
| Mar 03, 2023 |
POS AM filing: OKYO Pharma Limited is offering up to 5,381,166 American Depositary Shares and pre-funded warrants to purchase ADSs. |
290M | 0 |
| Dec 05, 2022 |
F-1 filing: OKYO Pharma Limited is offering 4,484,305 American Depositary Shares, each ADS represents 65 ordinary shares. |
290M | 4.5M |
| Aug 15, 2022 |
20-F filing | 1374.4M shares outstanding |
1.4B | 0 |
| Mar 04, 2022 |
F-1 filing: This is an F-1 filing related to an offering of ADSs (American Depositary Shares) representing ordinary shares of OKYO Pharma Limited. The company intends to use the net proceeds from the offering to advance OK-101 to the filing of an IND, to fund the start of the first Phase 2 clinical trial of OK-101 and for working capital and other general corporate purposes. |
N/A | 0 |